TY  - GEN
AU  - Mavratzas,A
AU  - Baek,S
AU  - Gerber,B
AU  - Schmidt,M
AU  - Moebus,V
AU  - Foerster,F
AU  - Grischke,E M
AU  - Fasching,P
AU  - Strumberg,D
AU  - Solomayer,E
AU  - Klare,P
AU  - Windemuth-Kieselbach,C
AU  - Hartmann,S
AU  - Schneeweiss,A
AU  - Marmé,F
TI  - Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study
SN  - 1532-3080
PY  - 2019///1203
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Angiogenesis Inhibitors
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Docetaxel
KW  - Double-Blind Method
KW  - Drug Administration Schedule
KW  - Female
KW  - Humans
KW  - Middle Aged
KW  - Progression-Free Survival
KW  - Receptor, ErbB-2
KW  - metabolism
KW  - Sorafenib
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
UR  - https://doi.org/10.1016/j.breast.2019.02.002
ER  -